01 · Product thesis
The core technical question is specific: can a lower-abdomen wearable generate a stable enough estimate of bladder filling to support a private pre-void cue? Ultrasound is the lead candidate because published research has explored wearable bladder monitoring. Bioimpedance and adjacent modalities remain open until bench and overnight data show what survives real use.
02 · System architecture
Four layers, each still open: body interface, sensing modality, on-device estimation, and private alert delivery. Each one has to hold before the next matters.
A soft lower-abdomen patch has to maintain contact through sleep, movement, and body-position changes before any signal promise matters.
Ultrasound is the lead candidate, with adjacent modalities held open until bench work shows which path best balances signal quality, comfort, power, and cost.
The first useful model is deliberately simple: an estimate of whether the bladder is filling consistently enough to justify a threshold alert.
A child wristband and optional caregiver device should receive only the minimum event information needed to act, not a stream of intimate raw data.
Architecture rules
Feasibility first
No sophisticated product layer matters if the abdomen signal is weak, unstable, or too power-hungry for overnight wear.
Minimal data path
The architecture is being framed to keep raw sensing close to the patch and move only threshold-level outputs downstream.
Family-safe failure modes
If the system is uncertain, it should degrade conservatively instead of pretending precision it has not earned.
The sensing stack and device boundaries will change as feasibility data comes in.
03 · Feasibility path
First establish that a usable signal exists. Then show the system survives real nights. Then decide whether broader validation is warranted.
Stage 01
01 / 04
Decision question: Can any noninvasive modality produce a stable, repeatable bladder-related signal under realistic placement conditions?
What this stage should settle
Stage 02
02 / 04
Decision question: Can children or families tolerate the form factor long enough for repeated overnight use?
What this stage should settle
Stage 03
03 / 04
Decision question: Does the signal hold in real nightly conditions well enough to justify a larger validation path?
What this stage should settle
Stage 04
04 / 04
Decision question: What evidence package is actually required before discussing clinical usefulness or commercial readiness?
What this stage should settle
04 · Validation roadmap
Each phase answers one concrete proof question, sized to where the company actually is: pre-prototype, and not clinically validated.
A rolling 90-day plan. Phases restate as gates close.
0–30 days
phase 01 of 03
Define the first claim as pre-void cue feasibility, not bedwetting treatment.
Decision gate
Is the first claim defined tightly enough to test?
31–60 days
phase 02 of 03
Compare candidate sensing paths against the realities of overnight pediatric wear.
Decision gate
Is there a signal path worth prototyping on the body?
61–90 days
phase 03 of 03
Turn the technical experiment into a study-ready product program.
Decision gate
Is DryNight ready for a controlled prototype build and clinician-reviewed feasibility plan?
Known risks
Any one of these can kill the product. The feasibility work exists to find out which ones do.
DryNight is not FDA-cleared, not clinically validated, and not available for diagnosis, treatment, or medical decision-making. The current work is feasibility, human factors, and study design.
05 · Why ultrasound, for now
Ultrasound is being explored because it could, in principle, observe bladder filling directly enough to support a pre-void cue. That still leaves the work that matters: proving the signal, the body interface, and that the alert reduces burden rather than adding one.
The lead method should be able to observe bladder-state changes directly enough to justify a pre-void cue. Miniaturization, coupling, motion tolerance, and power budget remain open engineering gates.
The sensor must stay positioned through sleep without making the child feel like a patient in a study. Adhesion, comfort, heat, charging, and cleaning matter as much as signal quality.
The useful output is one conservative decision point, tested against real nights, false cues, missed cues, and caregiver burden.
06 · Evidence room
Why the idea is plausible, where the first risk sits, and what has to be proven before any family is asked to trust it.
83%
of natural overnight bladder-filling cycles (15 of 18) were detected at home by the SENS-U in 14 children with enuresis, the setting closest to DryNight’s.
[1] Kwinten et al., 2020 ↗90%
of a controlled clinic urodynamic study (30 children, ages 6–12) had a full, catheter-filled bladder recognized before voiding by the SENS-U. A controlled-fill benchmark, not an overnight result.
[2] van Leuteren et al., 2018 ↗External findings, not DryNight performance data. They measure detection under different conditions, and in both studies the device only monitored: its alerts were switched off. Neither tested waking a child, so the hardest part of DryNight’s thesis (a cue that rouses a deep sleeper) has no precedent and must be earned.
Problem reality
Before any technical proof, the problem itself has to justify a better product: timing, dignity, and caregiver burden.
Bedwetting is common in school-age children and often resolves gradually rather than immediately. [3]
Most household alarms start only when wetting begins, long after the bladder first becomes actionable. [3][4]
Families need earlier information and less public interruption; a louder signal after wetness reaches clothing or bedding delivers neither. [4]
Technical precedent
Both studies below used a wearable ultrasound bladder sensor (the SENS-U), sold for daytime use in children. That a commercial device already estimates bladder state in this age group makes the sensing approach realistic. DryNight is building the overnight system that category has never attempted: the private cue, the escalation plan, and the home experience.
The SENS-U wearable ultrasound sensor detected full bladders before voiding in 90% of a 30-child urodynamic cohort aged 6 to 12. [2][6]
In a single-night home session, the SENS-U detected 83% of natural nocturnal bladder-filling cycles (15 of 18) in children with monosymptomatic nocturnal enuresis, without disturbing sleep. [1]
Noninvasive bladder monitoring is an active research area across ultrasound, bioimpedance, optical sensing, and flexible ultrasonic devices. [6][7]
Product thesis
The winning product here is a private timing system that fits the home. The sensor is only one part of it.
The first product is a soft lower-abdomen patch, a private wearer cue, and optional caregiver escalation.
The first milestone is timely pre-void cueing, before wetness starts.
The same timing problem can later support adult, older-adult, and caregiver workflows once the pediatric proof point is earned.
Validation milestones
This is the work between a strong idea and a product families can trust.
Select the sensing architecture that survives body-size variation, sleep position, motion, adhesion, and power constraints. [6][7]
Define an actionable threshold that balances missed cues, false cues, wearer comfort, and caregiver burden.
Run repeated-night usability and a clinician-reviewed pilot before expanding the market story. [3][4]
References
Single-night, at-home feasibility session in 14 children (of 15 enrolled) with monosymptomatic nocturnal enuresis. The SENS-U detected 83% of natural nocturnal bladder-filling cycles (15 of 18); the 3 missed cycles fell below the sensor’s volume detection limit. It did not disturb sleep.
Pediatric urodynamic-room study in 30 children aged 6 to 12. A wearable lower-abdomen ultrasound sensor detected the full bladder before voiding in 90% of patients (27 of 30). The device studied is the SENS-U (Novioscan).
Supports burden, spontaneous resolution, and the current standard of alarms plus desmopressin for many children.
Clarifies that alarms detect when wetting starts, often require sustained family effort, and are not ideal for every household.
The ICCS standard separates enuresis into nocturnal polyuria (overnight output above 130% of expected bladder capacity, desmopressin-first), reduced nocturnal bladder capacity, and disordered arousal. It defines expected bladder capacity as (age + 1) x 30 mL and grounds why a pre-void cue fits some children, not all.
Summarizes ultrasound, optical, and bioimpedance approaches for non-invasive bladder monitoring and highlights the field's current limits.
Shows that wearable ultrasound bladder sensing is technically plausible in research settings, while still distinct from a validated pediatric product.
Hygiene company Essity acquired Novioscan, maker of the SENS-U pediatric bladder sensor, confirming the modality is a real commercial category, not only a research idea.
Diligence
The SENS-U (Novioscan, acquired by Essity) is a real wearable ultrasound bladder sensor for children, and the two pediatric studies cited here used it. That is a strength: it proves the modality can estimate bladder state in this population. SENS-U is built around daytime full-bladder notifications and urotherapy, and in both cited studies its alerts were switched off, so it was never asked to wake a sleeping child. DryNight is scoped differently: a nocturnal timing system whose hardest, unproven job is a private cue that actually rouses a deep sleeper. The product is the overnight experience; the sensor is one component of it.
Nocturnal enuresis is not one condition. The ICCS separates it into nocturnal polyuria (the kidney overproduces at night, treated first with desmopressin), reduced nocturnal bladder capacity, and a deep-sleep arousal problem, often mixed. A pre-void cue fits the reduced-capacity and arousal children, where there is a fill-to-threshold window and a void to get ahead of. It is a poor fit for polyuria-dominant children, who can out-produce any reasonable wake schedule. The feasibility plan screens for phenotype, sets the cue threshold relative to each child’s expected bladder capacity, and pre-specifies reduced-capacity children as the primary population rather than treating enuresis as monolithic.
Sensing is necessary but not sufficient. Adoption in pediatric enuresis is governed by comfort, overnight wearability, false-alarm burden, caregiver fatigue, and whether the cue actually rouses a deep-sleeping child. DryNight treats those as the first product gates, not afterthoughts, which is why the feasibility plan logs comfort and arousal as primary outcomes.
The unmet need is earlier, quieter, more private timing. A product that can identify a useful pre-void window has a different value proposition for families, pediatric continence care, older-adult care, and long-term caregiver workflows.
The literature already includes noninvasive bladder monitoring, wearable ultrasound work, pediatric urodynamic testing, and overnight home monitoring in children with nocturnal enuresis. That is enough to justify feasibility work, especially if DryNight stays focused on a small first milestone.
DryNight would be a software-driven wearable medical device, so the path runs through the FDA. The intended approach is least-burdensome: a pre-submission (Q-Sub) meeting before any performance claim, then a 510(k) if a suitable predicate exists in the bladder-sensing class, or a De Novo if it does not. Nothing is filed yet, and no clearance is claimed; intended use and claim language will be set with regulatory counsel before a pilot generates performance data.
Signal quality under real overnight conditions. The system must handle motion, sleep position, body variation, sensor coupling, adhesion, battery life, and the difference between a useful trend and noise.
Specific de-risking: bench signal quality, a wearable form factor, repeated-night comfort, a defensible cue threshold, and a clinician-reviewed pilot protocol. Each is concrete enough for investors, advisors, and device partners to pressure-test.
Because a small, specific milestone can be tested, funded, and defended. Pediatric nocturnal enuresis is that milestone. Adult and older-adult continence workflows become stronger expansion paths after the signal, comfort, and cue logic are validated.
What would move this forward
DryNight needs advisors who can turn the first milestone into a study plan that matters clinically and commercially.
The hardware path has to be comfortable, low-power, manufacturable, and strong enough for repeated overnight wear.
The business path should finance the right proof, protect the first milestone, and keep the broader market in view.
Contact
DryNight needs grounded input from families, clinicians, engineers, care operators, and investors while the concept becomes a device. Use this form for feedback, research conversations, partnership ideas, manufacturing leads, or funding conversations.
What happens next
Every note is read by Elvis. Follow-up happens when a real conversation would help, and your address never lands on a mailing list.
The fastest way to shape this product is to tell us where it would fail in your home, clinic, or facility.